Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands.
J Diabetes Metab Disord
; 20(2): 1155-1160, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1286208
ABSTRACT
Purpose:
Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study.Methods:
We studied in 565 patients with type 2 diabetes in the CovidPredict Clinical Course Cohort whether use of a DPP-4 inhibitor prior to hospital admission due to COVID-19 was associated with improved clinical outcomes. Using crude analyses and propensity score matching (on age, sex and BMI), 28 patients using a DPP-4 inhibitor were identified and compared to non-users.Results:
No differences were found in the primary outcome mortality (matched-analysis = odds-ratio 0,94 [95% confidence interval 0,69 - 1,28], p-value 0,689) or any of the secondary outcomes (ICU admission, invasive ventilation, thrombotic events or infectious complications). Additional analyses comparing users of DPP-4 inhibitors with subgroups of non-users (subgroup 1 users of metformin and sulphonylurea; subgroup 2 users of any insulin combination), allowing to correct for diabetes severity, did not yield different results.Conclusions:
We conclude that outpatient use of a DPP-4 inhibitor does not affect the clinical outcomes of patients with type 2 diabetes who are hospitalized because of COVID-19 infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Language:
English
Journal:
J Diabetes Metab Disord
Year:
2021
Document Type:
Article
Affiliation country:
S40200-021-00833-z
Similar
MEDLINE
...
LILACS
LIS